Target Name: TERF2IP
NCBI ID: G54386
Other Name(s): Dopamine receptor interacting protein 5 | TERF2-interacting telomeric protein 1 | Telomeric repeat binding factor 2, interacting protein, isoform CRA_a | Repressor/activator protein 1 homolog | TRF2-interacting telomeric protein 1 | Dopamine receptor-interacting protein 5 | Telomeric repeat-binding factor 2-interacting protein 1 | TERF2 interacting protein, transcript variant 1 | hRap1 | repressor/activator protein 1 homolog | DRIP5 | RAP1 homolog | TERF2 interacting protein | dopamine receptor-interacting protein 5 | TE2IP_HUMAN | RAP1 | TRF2-interacting telomeric RAP1 protein | TERF2IP variant 1

TERF2IP: A Potential Drug Target and Biomarker

Terminal exonuclease 2-isoleucine repetitive fragment (TERF2IP) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. TERF2IP is expressed in various tissues and cell types, including the brain, heart, and pancreas, and has been shown to play a role in regulating gene expression and cellular processes.

The Discovery of TERF2IP as a Potential Drug Target

The discovery of TERF2IP as a potential drug target was based on its unique expression pattern in various tissues and cell types. Initial studies identified TERF2IP as highly expressed in the brain and heart, which are known to be critical for the development and progression of neurodegenerative diseases.

Further analysis of TERF2IP expression revealed that it was highly expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disease that is characterized by the progressive loss of brain cells. This suggests that TERF2IP may be a promising drug target for the treatment of Alzheimer's disease.

The Potential Benefits of TERF2IP as a Drug Target

If TERF2IP is proven to be a valid drug target, it has the potential to treat a wide range of neurodegenerative diseases. For example, TERF2IP has been shown to be highly expressed in the brains of individuals with Alzheimer's disease, which is a neurodegenerative disease that is characterized by the progressive loss of brain cells.

The loss of brain cells in Alzheimer's disease is thought to contribute to the development and progression of the disease. By targeting TERF2IP, researchers may be able to slow down or even reverse the progression of Alzheimer's disease.

In addition to its potential use in Alzheimer's disease, TERF2IP may also be a useful biomarker for the disease. The expression of TERF2IP has been shown to be elevated in the brains of individuals with Alzheimer's disease, which could be used as a diagnostic tool for the disease.

The Potential Risks of TERF2IP as a Drug Target

While the potential benefits of TERF2IP as a drug target for the treatment of neurodegenerative diseases are significant, there are also potential risks to consider. For example, it is not yet clear what the long-term effects of TERF2IP treatment will be on brain function and structure.

Additionally, the development of TERF2IP as a drug target may also raise ethical concerns about the use of human subjects for research and treatment. It is important to consider the potential impact of TERF2IP treatment on the rights and dignity of individuals who may be subject to the study.

Conclusion

In conclusion, TERF2IP is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique expression pattern in various tissues and cell types, as well as its potential role in the treatment of Alzheimer's disease, make it an promising target for further research. However, as with any new drug target, further studies are needed to fully understand its potential risks and benefits.

Protein Name: TERF2 Interacting Protein

Functions: Acts both as a regulator of telomere function and as a transcription regulator. Involved in the regulation of telomere length and protection as a component of the shelterin complex (telosome). In contrast to other components of the shelterin complex, it is dispensible for telomere capping and does not participate in the protection of telomeres against non-homologous end-joining (NHEJ)-mediated repair. Instead, it is required to negatively regulate telomere recombination and is essential for repressing homology-directed repair (HDR), which can affect telomere length. Does not bind DNA directly: recruited to telomeric double-stranded 5'-TTAGGG-3' repeats via its interaction with TERF2. Independently of its function in telomeres, also acts as a transcription regulator: recruited to extratelomeric 5'-TTAGGG-3' sites via its association with TERF2 or other factors, and regulates gene expression. When cytoplasmic, associates with the I-kappa-B-kinase (IKK) complex and acts as a regulator of the NF-kappa-B signaling by promoting IKK-mediated phosphorylation of RELA/p65, leading to activate expression of NF-kappa-B target genes

More Common Targets

TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2 | TGFBR3